CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,183 enrolled
Drug / intervention
Vonoprazandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03214952
NCT03214952N/ACompleted
CompareCT.gov

Drug Use Surveillance of Takecab Tablets for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Takeda·observational·Posted Jul 12, 2017·Updated Dec 12, 2019

In Brief

An observational study evaluating Vonoprazan for Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis. Completed, enrolled 3,183 participants across 1 site.

Detailed Summary

The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 12, 2017
Enrollment StartMar 1, 2016
Primary CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.0 years ago

Interventions

Vonoprazandrug

Vonoprazan tablets